This article was originally published in Start Up
Executive SummarySequella Inc. believes that the technology to meet antibiotic-resistant mycobacterium tuberculosis already exists. The company will acquire intellectual property rights to product opportunities in TB.
You may also be interested in...
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.